Inovio Pharmaceuticals (INO) News
NASDAQ: INOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.15+0.06 (+5.50%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
INO news summary
We found 3 recent headlines mentioning Inovio Pharmaceuticals (INO): 2 in the past week and 3 in the past 30 days, most often from Nasdaq. INO is making an outsized move today, up 5.50% at $1.15, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Inovio Pharmaceuticals headlines
- FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerPfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.NasdaqPFE, INO
- PGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowPrecigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.NasdaqPGEN, MRK, INO
- Biotech Stocks Facing FDA Decision In October 2026(RTTNews) - The FDA's October decision calendar looks relatively light, with only a limited number of PDUFA dates scheduled.NasdaqGSK, INO, IRD